Logo image of SAVA

CASSAVA SCIENCES INC (SAVA) Stock Fundamental Analysis

USA - NASDAQ:SAVA - US14817C1071 - Common Stock

3.26 USD
+0.15 (+4.82%)
Last: 11/12/2025, 8:00:02 PM
3.23 USD
-0.03 (-0.92%)
After Hours: 11/12/2025, 8:00:02 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SAVA. SAVA was compared to 191 industry peers in the Pharmaceuticals industry. While SAVA seems to be doing ok healthwise, there are quite some concerns on its profitability. SAVA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SAVA had negative earnings in the past year.
In the past year SAVA has reported a negative cash flow from operations.
In the past 5 years SAVA always reported negative net income.
In the past 5 years SAVA always reported negative operating cash flow.
SAVA Yearly Net Income VS EBIT VS OCF VS FCFSAVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

SAVA has a Return On Assets of -90.98%. This is in the lower half of the industry: SAVA underperforms 75.92% of its industry peers.
The Return On Equity of SAVA (-140.01%) is worse than 67.02% of its industry peers.
Industry RankSector Rank
ROA -90.98%
ROE -140.01%
ROIC N/A
ROA(3y)-37.34%
ROA(5y)-26.18%
ROE(3y)-40.31%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
SAVA Yearly ROA, ROE, ROICSAVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

SAVA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SAVA Yearly Profit, Operating, Gross MarginsSAVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for SAVA has been increased compared to 1 year ago.
The number of shares outstanding for SAVA has been increased compared to 5 years ago.
SAVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SAVA Yearly Shares OutstandingSAVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SAVA Yearly Total Debt VS Total AssetsSAVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

SAVA has an Altman-Z score of -5.56. This is a bad value and indicates that SAVA is not financially healthy and even has some risk of bankruptcy.
SAVA has a worse Altman-Z score (-5.56) than 61.78% of its industry peers.
There is no outstanding debt for SAVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.56
ROIC/WACCN/A
WACCN/A
SAVA Yearly LT Debt VS Equity VS FCFSAVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 2.43 indicates that SAVA has no problem at all paying its short term obligations.
SAVA has a Current ratio (2.43) which is in line with its industry peers.
SAVA has a Quick Ratio of 2.43. This indicates that SAVA is financially healthy and has no problem in meeting its short term obligations.
SAVA has a Quick ratio (2.43) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.43
Quick Ratio 2.43
SAVA Yearly Current Assets VS Current LiabilitesSAVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

SAVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.50%, which is quite impressive.
EPS 1Y (TTM)37.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-787.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 102.72% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-35.77%
EPS Next 2Y8.81%
EPS Next 3Y102.72%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SAVA Yearly EPS VS EstimatesSAVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SAVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SAVA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SAVA Price Earnings VS Forward Price EarningsSAVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SAVA Per share dataSAVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as SAVA's earnings are expected to grow with 102.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.81%
EPS Next 3Y102.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SAVA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CASSAVA SCIENCES INC

NASDAQ:SAVA (11/12/2025, 8:00:02 PM)

After market: 3.23 -0.03 (-0.92%)

3.26

+0.15 (+4.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05
Earnings (Next)03-02 2026-03-02/amc
Inst Owners25.22%
Inst Owner Change-1.17%
Ins Owners5.73%
Ins Owner Change0.76%
Market Cap157.49M
Revenue(TTM)N/A
Net Income(TTM)-123.17M
Analysts80
Price Target5.1 (56.44%)
Short Float %16.25%
Short Ratio2.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)150%
PT rev (3m)150%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-250.91%
EPS NY rev (3m)-250.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.79
P/tB 1.79
EV/EBITDA N/A
EPS(TTM)-1.45
EYN/A
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)-1.99
FCFYN/A
OCF(TTM)-1.98
OCFYN/A
SpS0
BVpS1.82
TBVpS1.82
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -90.98%
ROE -140.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.34%
ROA(5y)-26.18%
ROE(3y)-40.31%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.43
Quick Ratio 2.43
Altman-Z -5.56
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)81.28%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-787.31%
EPS Next Y-35.77%
EPS Next 2Y8.81%
EPS Next 3Y102.72%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.94%
OCF growth 3YN/A
OCF growth 5YN/A

CASSAVA SCIENCES INC / SAVA FAQ

What is the ChartMill fundamental rating of CASSAVA SCIENCES INC (SAVA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SAVA.


Can you provide the valuation status for CASSAVA SCIENCES INC?

ChartMill assigns a valuation rating of 1 / 10 to CASSAVA SCIENCES INC (SAVA). This can be considered as Overvalued.


What is the profitability of SAVA stock?

CASSAVA SCIENCES INC (SAVA) has a profitability rating of 0 / 10.


How financially healthy is CASSAVA SCIENCES INC?

The financial health rating of CASSAVA SCIENCES INC (SAVA) is 6 / 10.


Can you provide the expected EPS growth for SAVA stock?

The Earnings per Share (EPS) of CASSAVA SCIENCES INC (SAVA) is expected to decline by -35.77% in the next year.